Ysios Capital has supplied a series A extension that follows an initial tranche co-led by Kurma Partners and Sunstone Life Science Ventures in November 2020.

Julius-Maximilians-University of Würzburg's cancer immunotherapy developer Catalym plans to move its lead asset into the clinic next month.

Legend Capital was among the participants as Rec-Biotechnology raised series B funding that will be used for clinical trials of its vaccine candidates.

The genitourinary tumour drug developer's latest round follows a June series C-plus round featuring C&D, Tigermed and SAIC Capital.

3M Ventures and NTTVC joined new and existing investors to help the cardiopulmonary virtual care provider boost its overall funding to $92m.

Novartis Venture Fund took part in a series B round closed as Catalym prepares to move its lead cancer immunotherapy asset into the clinic next month.

Tasly took part in a $30.2m round for medical imaging services provider Keya Medical Technology, which has now raised cash three times this year.

Nestlé and Cedars-Sinai Medical Center participated in a round that came four months after the precision IBD therapy developer rebranded from Precision IBD.

Corporate venturing units GV and SR One both reinvested as the hearing loss therapy developer pushed its overall funding past the $190m mark.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.